Hanger — Investor Presentation (August 2012)
29 slides from Hanger's investor presentation, Aug 6, 2012
Slide 1: Investor Presentation: 150 Years of Empowering Human Potential
150 YEARS Investor Presentation of Empowering Human Potential. August 2012
Slide 2: Safe Harbor
SAFE HARBOR Except for the historical information contained herein, the matters discussed in this presentation constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. These include the rate at which Hanger
Slide 3: Vision
VISION Be the partner of choice for products and services that enhance human physical capability. 2
Slide 4: Overview
OVERVIEW 3 $953 million in revenues LTM Adjusted EBITDA $155 million LTM
Slide 5: Overview
OVERVIEW 4 DISTRIBUTION 11% of revenues $105 million revenue THERAPEUTIC SOLUTIONS 7 % of revenues $63 million revenue ACP, Inc. IN, Inc. PATIENT CARE 82 % of revenues LTM $785 million revenue LTM Linkia $953 million in revenues LTM Adjusted EBITDA $155 million LTM
Slide 6: Overview
OVERVIEW 5 $953 million in revenues LTM Adjusted EBITDA $155 million LTM THERAPEUTIC SOLUTIONS 7 % of revenues $63 million revenue ACP, Inc. IN, Inc. DISTRIBUTION 11% of revenues $105 million revenue PATIENT CARE 82 % of revenues LTM $785 million revenue LTM Linkia
Slide 7: Overview
OVERVIEW 6 $953 million in revenues LTM Adjusted EBITDA $155 million LTM THERAPEUTIC SOLUTIONS 7 % of revenues $63 million revenue ACP, Inc. IN, Inc. DISTRIBUTION 11% of revenues $105 million revenue PATIENT CARE 82 % of revenues LTM $785 million revenue LTM Linkia
Slide 8: Disciplined Diversification of Revenue
DISCIPLINED DIVERSIFICATION OF REVENUE 7 $4.6 Billion Addressable Market 29% 10%
Slide 9: Compelling Growth Drivers
COMPELLING GROWTH DRIVERS 8 Sources: Company estimates; Wall Street Research; 2003–2006 National Health and Nutrition Examination Survey; National Institutes of Health; Amputee Coalition of America. Aging Population (U.S.) (%) Diabetes – Prevalence By Age Group Disease and aging population Advancing
Slide 10: Patient Care
PATIENT CARE 9
Slide 11: Profile: Patient Care
10 PROFILE PATIENT CARE One or more certified clinicians Technical personnel Office administrators Line of site incentives to grow revenues and collect receivables CAGR up 6.7% (2008–2011) Business Overview Center Overview Over 700 O&P patient-care centers Over 1,195 O&P certified and licensed clini
Slide 12: Market Position: Patient Care
11 MARKET POSITION PATIENT CARE Only national or regional provider Hanger operates ~25% of accredited O&P facilities No other provider has more than 2% market share Adjacent market of $1.4 Billion Principal Reimbursement Sources for Patient Care Services $2.6 Billion US Market
Slide 13: Patient Care Growth Opportunities
PATIENT CARE First to market with new technologies and products Linkia Network Management Diversification into new adjacent businesses CARES Dosteon Solutions Small O&P acquisitions Sales synergies with ACP 12 GROWTH OPPORTUNITIES
Slide 14: Linkia Network Management
LINKIA First and only O&P network management company Insurers’ exclusive or preferred provider of their network Hanger network of approximately 1,050 O&P centers 53 contracts; 1–3 years; auto renew Value proposition to large name companies through expanded services 28% CAGR of contracted revenues (2
Slide 15: Distribution
DISTRIBUTION 14
Slide 16: Distribution Profile
DISTRIBUTION Largest dedicated distributor of O&P devices and components Over 29,000 O&P related items 6 strategically located distribution facilities Comprehensive Customer Service Manufacture and distribute therapeutic footwear Net sales $105 million LTM and CAGR of 7.6% (2008–2011) Inter-company
Slide 17: Distribution Opportunities
DISTRIBUTION Increase depth and breadth of product line Increase penetration of existing customer base Expand customer base Expand market presence geographically Apply core competencies to adjacent businesses Expand O&P fabrication operation to Independent O&P Providers 16 OPPORTUNITIES
Slide 18: Therapeutic Solutions
THERAPEUTIC SOLUTIONS 17
Slide 19: Therapeutic Solutions: Diversification of Revenue
THERAPEUTIC SOLUTIONS Innovative Neurotronics Development and commercialization of products V-Hold and WalkAid Accelerated Care Plus (ACP) Value proposition to rehabilitation providers Technology, clinical modalities, training and education 18 DIVERSIFICATION OF REVENUE
Slide 20: ACP Overview
ACP OVERVIEW 19 ACP enables post-acute providers with 24 evidence-based clinical therapy programs Physical Agent Modality Basics Wound Healing Fall Prevention Continence Improvement Contracture Management Pain Management Physical Agent Modality Basics Osteoarthritis of the Knee Orthotic Therapy Hemi
Slide 21: Financial Overview
FINANCIAL OVERVIEW 20
Slide 22: Solid Financial Position
SOLID FINANCIAL POSITION Earnings and margin growth Substantial cash flow generation Strong balance sheet management Moderate leverage post ACP acquisition Consistent reduction of leverage 21
Slide 23: Q2 2012 in Review
Q2 2012 IN REVIEW Same Store Sales 4.6% 8.9% growth in Adjusted EBITDA 11.1% increase in earnings per share Leverage ratio to 2.88X Total liquidity at 6/30/2012 was $141.1 Million including $41.6 of cash Total Debt $504.4 Million 22
Slide 24: Revenue Growth
REVENUE GROWTH 23 ($ in millions)
Slide 25: Adjusted EBITDA Growth and Margins
ADJUSTED EBITDA GROWTH AND MARGINS* 24 CAGR 16.4% Excludes relocation expenses and cost related to acquisitions. Adjusted EBITDA Adjusted EBITDA Margins % ($ in millions)
Slide 26: Growth in Adjusted EPS
GROWTH IN ADJUSTED EPS* 25 * Excludes relocation expenses, cost related acquisitions and the accelerated non-cash preferred dividend in 2008. ($ in millions)
Slide 27: Steady Comparable Quarter Growth
STEADY COMPARABLE QUARTER GROWTH 26 2010 2011 2012 Adjusted EBITDA* ($ in millions) * Excludes relocation expenses and cost related to the ACP acquisition. Revenues ($ in millions) Adjusted Earnings Per Diluted Share* * Excludes relocation expenses, cost related to the ACP acquisition and accelerate
Slide 28: Key Investment Points
KEY INVESTMENT POINTS Compelling industry growth drivers Dominant market position Attractive organic growth opportunities Adjacent continuum of care opportunities Proven acquisition capabilities Solid financial position 27
Slide 29: Hanger: Empowering Human Potential
~* Hanger -* Hanger Empowering Human Potential (NYSE: HGR) * Hanger CLINIC Empowering Hur BD» POSTEON LINKIA CAS >SPS INNOVATIVE NEUROTRONICS